1-3 of 3
Brendan Hodkinson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the impact of MCL35 score and TP53 Mutation Status

Ciara L Freeman, Srimathi Srinivasan, Brendan Hodkinson, Sanjay Deshpande, Todd Henninger, Merrill Boyle, Michael L Wang, Martin Dreyling, David W. Scott
Journal: Blood
Blood blood.2024026003.
https://doi.org/10.1182/blood.2024026003
Published: 2025
Includes: Supplemental data
Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 354.
https://doi.org/10.1182/blood-2019-124443
Published: 2019
Journal Articles

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, MD, Nathan H. Fowler, MD, Judith Trotman, Georg Hess, Bruce Cheson, MD, Michael Schaffer, PhD, Shean-Sheng Wang, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4147.
https://doi.org/10.1182/blood-2018-99-116472
Published: 2018